ESOPJun 3, 2026, 07:31 AM
REGENXBIO Approves Non-Executive Stock Option Exchange Program
AI Summary
REGENXBIO Inc. held its 2026 Annual Meeting of Stockholders on May 29, 2026, with 82.95% of shares represented. Stockholders elected three Class II directors, ratified PricewaterhouseCoopers LLP as the independent auditor, and approved executive compensation on an advisory basis. Importantly, the company's Stock Option Exchange Program for non-executive employees was approved, while a similar program for executive employees was not approved. The approved non-executive program commenced on June 3, 2026, allowing eligible participants to exchange certain outstanding stock options for new options at fair market value.
Key Highlights
- REGENXBIO's 2026 Annual Meeting of Stockholders had 82.95% of shares represented.
- Three Class II directors were elected to serve until the 2029 annual meeting.
- Stockholders ratified PricewaterhouseCoopers LLP as the independent auditor for 2026.
- Stockholders approved, on an advisory basis, the compensation of named executive officers.
- The Stock Option Exchange Program for non-executive employees was approved with 26,352,456 votes For.
- The Stock Option Exchange Program for executive employees was not approved with 21,021,531 votes Against.
- The non-executive Stock Option Exchange Program commenced on June 3, 2026, concluding July 1, 2026.
- Eligible non-executive employees can exchange options with an exercise price at or above $18.00.
Price Impact
More from RGNX